MoonLake Immunotherapeutics Receives Unanimous Support for Phase 3 Trial of Sonelokimab in Hidradenitis Suppurativa from FDA and EMA Company: MoonLake Immunotherapeutics Indication: Hidradenitis Suppurativa (HS) Drug: Sonelokimab (SLK) Trial Phase: Phase 3 NCT ID: NCT05322473 Overview MoonLake Immunotherapeutics, a clinically-focused biopharmaceutical company, has announced a significant milesto..
BioCity Biopharma Completes Enrollment for IgA Nephropathy Cohort in Phase II Trial of SC0062 Company: BioCity Biopharma Indication: IgA nephropathy (IgAN), chronic kidney disease (CKD), diabetic kidney disease (DKD) Drug: SC0062 Trial Phase: Phase 2 NCT ID: Not provided Overview BioCity Biopharma has announced the successful completion of patient enrollment for the IgA nephropathy (IgAN) cohort..
Enhanced Risk Stratification in Stage I Melanoma Patients Using DecisionDx-Melanoma Overview Company: Castle Biosciences, Inc. Indication: Stage I Cutaneous Melanoma (CM) Drug/test: DecisionDx-Melanoma Test Trial Phase: Not Applicable NCT ID: Not Available Background Castle Biosciences, Inc. announced on February 26, 2024, a significant enhancement in risk stratification for Stage I Cutaneous Me..
Preliminary Results Display Full Tumor Eradication in Non-surgical Breast Cancer Patients Using IceCure's ProSense® Cryoablation Therapy Overview Company: IceCure Medical Ltd. Indication: Early-Stage Breast Cancer Drug/Treatment: ProSense® System Trial Phase: Not applicable NCT ID: Not available Study Summary In a groundbreaking study led by Dr. Federica di Naro at Azienda Ospedaliero-Universita..
NewBiologix Engages with Florabio to Transform Gene Therapy Manufacturing through Advanced HEK293 Cell Line Engineering Company: NewBiologix SA Indication: Not Applicable Drug: Recombinant adeno-associated virus (rAAV) vectors Trial Phase: Not Applicable NCT ID: Not Available Overview On February 27, 2024, NewBiologix SA, a biotech firm based in Lausanne, Switzerland, announced a strategic partn..
Akili and Shionogi Declare Success in Phase 3 Clinical Trial for EndeavorRx as ADHD Treatment for Japanese Children Overview Company: Akili, Inc. & Shionogi & Co. Ltd Indication: Pediatric ADHD Drug: SDT-001 (localized version of AKL-T01 / EndeavorRx) Trial Phase: Phase 3 NCT ID: N/A Akili, Inc., in collaboration with Shionogi & Co. Ltd, announced the successful completion of a Phase 3 clinical ..
Bitterroot Bio and Biotheus Forge Partnership for Bispecific Protein Development in Cardiovascular Immunotherapy Overview Company: Bitterroot Bio; Biotheus Indication: Cardiovascular diseases Drug: N/A Trial Phase: N/A NCT ID: N/A Details In a significant stride within the field of cardio-immunology, Bitterroot Bio and Biotheus have publicly announced the establishment of a multi-year research c..
